New weekly diabetes shot shows promise in large trial
NCT ID NCT06235086
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tested a new weekly injection called TG103, combined with the common diabetes pill metformin, in 632 adults with type 2 diabetes. The goal was to see if TG103 could lower blood sugar better than an existing weekly shot (dulaglutide) over 28 weeks. Participants received either TG103 or dulaglutide, and researchers tracked changes in blood sugar levels, weight, and safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TG103 injection (a weekly shot) compared to dulaglutide (another weekly shot)
What this could lead to
If successful, this could offer a new weekly injection option to help people with type 2 diabetes better control their blood sugar and possibly lose weight.
What could go wrong
This is a completed Phase 3 trial, but results are not yet published. The drug may not prove superior to existing options, and side effects like gastrointestinal issues are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University People's Hospital
Beijing, Beijing Municipality, 100032, China